1-3 of 3 results for subject:Pfizer
Librarians' tools
- Search time
- 0.167 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Legislative stage
Legislation
Subject
Publisher
To ask Her Majesty's Government what scientific evidence they have on the effectiveness of the (1) Pfizer, and (2) Astra Zeneca, vaccines in reducing (a) hospitalisations, and (b) symptomatic infections, linked to the B1.351 COVID-19 variant; and what plans they have to publish this evidence.
To ask Her Majesty's Government what scientific evidence they have on the effectiveness of the (1) Pfizer, and (2) Astra Zeneca, vaccines in reducing (a) hospitalisations, and (b) symptomatic infections, linked to the B1.351 COVID-19 variant; and what plans they have to publish this evidence.
Public Health England (PHE) is researching the effectiveness of the Pfizer and AstraZeneca vaccines against the B1.351 variant. PHE will publish advice in the weekly COVID-19 vaccine surveillance report once sufficient data is available.
Lords private notice question on what plans they have to ensure that the second dose of the Pfizer/BioNTech COVID-19 vaccine is delivered to patients within 12 weeks of receiving the first dose.
Lords private notice question on what plans they have to ensure that the second dose of the Pfizer/BioNTech COVID-19 vaccine is delivered to patients within 12 weeks of receiving the first dose.
Lords private notice question on what evidence they have that delaying a second dose of the Pfizer-BioNTech Covid-19 vaccine will not (1) diminish its effectiveness, or (2) cause further mutations in the virus.
Lords private notice question on what evidence they have that delaying a second dose of the Pfizer-BioNTech Covid-19 vaccine will not (1) diminish its effectiveness, or (2) cause further mutations in the virus.